scispace - formally typeset
T

Takashi Nakano

Researcher at Hyogo College of Medicine

Publications -  112
Citations -  6502

Takashi Nakano is an academic researcher from Hyogo College of Medicine. The author has contributed to research in topics: Mesothelioma & Lung cancer. The author has an hindex of 27, co-authored 110 publications receiving 5000 citations.

Papers
More filters
Journal ArticleDOI

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

Peter Goldstraw, +142 more
TL;DR: The methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition of the TNM Classification for lung cancer due to be published late 2016 are described.
Journal ArticleDOI

The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

William D. Travis, +78 more
TL;DR: Codes for the primary tumor categories of AIS and minimally invasive adenocarcinoma (MIA) and a uniform way to measure tumor size in part‐solid tumors for the eighth edition of the tumor, node, and metastasis classification of lung cancer are proposed.
Journal ArticleDOI

Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer

TL;DR: Among lung cancer patients, CTC count significantly increased along with tumor progression, especially with development of distant metastasis, but a receiver operating characteristic (ROC) curve analysis showed an insufficient capability of the CTC test in discrimination between lung cancer and nonmalignant diseases.
Journal ArticleDOI

The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer

Frank C. Detterbeck, +164 more
TL;DR: An extensive analysis has produced stage classification proposals for lung cancer with a robust degree of discriminatory consistency and general applicability and external validation is encouraged to identify areas of strength and weakness.